Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Indeed...if played right by the BoD!
If they do still intend to call it that, I can just imagine the commercial...
"Get Eroxon, get Eroxon honey. Shake it now, now, get 'em off downtown"
:)
Taking these ludicrous assumtions further...
The cost of a Viagra pill is roughly around the $5 mark.
I'm going to make a wild estimate and say the gel is sold at say $1.5 per single use tube.
Revenues, like for like usage, would be around a quarter that of Viagra which might suggest $400m total revenue in the first year. Of which FUM might expect to receive $200m after licensing etc
$200m earnings would equate to... £10 per share.
Price 10
Shares 300,000,000
Earnings 200,000,000
Diluted EPS 0.666666666666667
P/E 15
MKCAP £3,000,000,000
Madness. Someone tell me I've got this totally wrong!!!
*Pfizer P/E = 16
**300m shares to account for options etc
Just running a quick amatuer comparison with Pfizer. I must be making some errors. These numbers are crazy.
Pfizer
MkCAP = $198bn
Earnings (profit) = $11.71bn
17:1
FUM
MkCAP = $10.5bn
Earnings (profit) = $600m
17:1
$600m is only a third to a quarter of the global Viagra market. The market for this gel is way bigger than that right?
Remember, in 1998 Viagra became the fastest selling drug in history.
Within three months of its launch, Viagra had already earned Pfizer $400m, and over the past two decades, it has consistently generated annual sales to the tune of around $1.8bn.
My strategy now with FUM is just to ask myself this simple question ...
When the next RNS comes out (almost certainly within the coming weeks), is it more likely to be positive or negative?
I could be wrong but I'm strongly leaning towards it being positive, in which case I'll be delighted in watching the share price as it rushes north.
Yup. Plenty of buyers it seems. I can sell everything I've got at 59p....now 60p.
If there is a takeover, and if it's an American corp, I'd expect them to wait til the FDA trials are complete before raising their heads. If all goes well, and there's no reason for me to suspect it wont, I think there will be a healthy premium on the share price.
Global Viagra revenues have been, on average just below £2bn per year for the past 20 years. If MED3000 does just one tenth of that, that would be £100m renenues per year after licensing (manufacturing and distrubution) which, unless my maths is wrong (and there's a good chance of that!), should put the share price somewhere around £9.
--
Shares 246,000,000
Earnings 100,000,000
Diluted EPS 0.40650406504065
P/E 22.14
In summary, if there's a buyout/takeover, I wouldn't expect the shareholdes to agree on anything less than £10 per share. That is, a MkCap ~£2.5bn.
Could be breaking out but what I'm most interested in is hearing more on what this means...
"Subject to shareholder approval, I am delighted to make a significant investment into the Company. The Board has ambitious plans for the rapid expansion of the business and the cash reserves we have now secured will kick-start this growth. "
Thanks mpl50, You raise some good points. However, the website does indeed have actual photos of the port...
https://www.mercpl.com/gallery/Photo/inauguration-ceremony-march-8-2019/33
Granted, not as shiny lookin as the computer generated "junk" ... but to your point when you say "There is no port " ... it's clear there is a port (or sorts).
This quote says it all ... "I look forward to updating the market as we close further contracts with pipeline customers throughout the course of the year".
Sounds very much like they have more contracts in the advanced stages of agreement.
Yup. I think this is one of the safest investments there is in the current climate.
- a household defensive, covid safe, company
- sticky ingredient (once in a formulation, it doesn't get removed easily )
- eco / esg
- ITX IP and patents
- $15m product capacity at existing plant (with minimal additional investment)
- growing customer base
- cash til at least the end of this year
- John Shaw :)
Only reason for the slight downward is the lack of clarity of last years results. We know they were good and we know they were "slightly ahead of current market expectations". Most likely means, they're not yet breaking even. However, they will and as soon as they do, this share will not stop rising. By my estimations we'll see 10p around $7m revenue and at least 20p at $9m.
Buy now and hold. Come 2022, ITX will be in high demand.
No, not much revenue at this stage
I guess the main point of Bitcoin is its decentralisation. The more people running a node, the more decentralised the network is and therefore, in theory, the stronger it is.
It would zap your bandwidth for sure when you initially download the blockchain (~500GB)...after that, its just downloading newly mined blocks.
One other benefit is that you can host your own bitcoin wallet as every full node is also a btc wallet. I think you can also run a lightning network node too meaning off-chain payments which in theory would be cheaper and faster.
Wonder if anyone has installed their own Bitcoin node with Umbrele?
Raspberry Pi, SSD and few cables. Total cost ~ £500 and apparently you're good to go...
https://getumbrel.com/
From Yahoo...
(https://finance.yahoo.com/news/otcqx-vs-otcqb-vs-pink-171211773.html)
OTCQX
The OTCQX Market is the top tier, with the most stringent entry requirements. According to OTC Markets, companies trading on OTCQX must “meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction.”
More specifically, these companies must meet a reporting standard in terms of how they report financial information. They must also have a board of directors with at least two independent directors, an audit committee that conducts annual financial audits, have annual shareholders meetings and release annual financial reports 15 days prior to each meeting.
Companies that are penny stocks, shells, or are in bankruptcy are excluded from trading on this tier.
Over 400 companies trade on OTCQX, including Swiss pharmaceutical conglomerate Roche (OTCQX: RHHBF) (OTCQX: RHHBY) (OTCQX: RHHVF), the French global communications company Publicis Groupe S.A. (OTCQX: PUBGY) (OTCQX: PGPEF) and Grayscale’s Investment the Bitcoin Investment Trust (OTCQX: GBTC).
OTCQB
The middle tier of OTC Markets – OTCQB – is known as The Venture Market. Companies that trade on this tier are in their early stages, and therefore, may not be able to meet the financial or regulatory requirements required by the exchanges or OTCQX.
To be eligible for OTCQB, companies must be current in their financial reporting, undergo an annual verification and management certification process, and have a bid price of at least $0.01. They also cannot be in bankruptcy. Over 900 companies trade on the OTCQB Market.
Eh... no seethreeIPO, I'm not "completely wrong".
I don't beleive I said an RNS should be an "implementation plan" or a "strategic detail document".
I simply said, I'd like more details.
You might be surprised to hear but in logical thought, someone cannot be wrong for stating a preference (" I would have preferred more detail ") .. However, you can be "completety wrong" for stating non-fact as fact. Hope that helps.